cardiology clinical cases...acc/aha 2017 guidelines hypertensive emergency bp > 180/110 with...
Post on 06-Oct-2020
3 Views
Preview:
TRANSCRIPT
9/11/2020
1
Cardiology Clinical CasesTeri Diederich, APRN-NPOctober 2, 2020
DisclosuresI have nothing to disclose
1
2
9/11/2020
2
Objectives 1. Verbalize hypertension and hyperlipidemia management guidelines 2. Describe management of atrial arrhythmias and use of CHADS-2-VASC3. Review diagnostic tools for dyspnea and exertional chest pain evaluation 4. Verbalize treatment options for heart failure patients
Case Study Mr Smith is a 58-year-old Caucasian male establishing care at your clinic as his employer now offices discounts with yearly exams. He has no past medical history and takes no meds. He quit smoking 3 years ago and smoked 1 ppd for 30 years.
Vitals –HR – 78, BP – 148/88, RR – 18, O2 – 99%
Labs –HgbA1C – 5.9 BMP – WNL TC – 187 mg/dLTG – 157 mg/dLHDL – 43 mg/dLLDL – 113 mg/dL
BMI – 41
3
4
9/11/2020
3
Questions What medical conditions does this patient have? What medications should this patient start taking?
Hypertension Categories Persistently elevated pressures in the vessels
ACC/AHA 2017 Guidelines
Hypertensive emergency BP > 180/110 with signs of end-organ damage
Hypertensive urgency elevated blood pressure without end-organ damage
5
6
9/11/2020
4
Secondary causes of hypertension
Endocrine Adrenal Renal Cardiovascular Drugs
• Cushing's syndrome
• Acromegaly• Thyroid
disease• Hyperpara‐
thyroid disease
• Conn's syndrome
• Adrenal hyperplasia
• Pheochromocytoma
• Diabetic nephropathy
• Chronic glomerulonephritis
• Adult polycystic kidney disease
• Renovascular disease
• Aortic coarctation
• Sleep apnea syndrome
• NSAIDs• Oral
contraceptive• Steroids• Carbenozalone• Licorice• Sympathomimet
ics• Vasopressin• Monoamine
oxidase inhibitors
• Chemotherapy agents
ACC/AHA 2017 Guidelines
7
8
9/11/2020
5
ASCVD Risk Calculator Age (years)GenderRaceTotal Cholesterol HDLSystolic blood pressureDiastolic blood pressureTreated for high blood pressure: no/yesDiabetes: no/yesSmoker: no/yes
cvriskcalculator.com
Oral AntihypertensivesPrimary agents • Thiazide or thiazide type
diuretics • ACE inhibitors • ARBs• Calcium Channel
Blockers (CCB)
Secondary Agents • Diuretics • Beta Blockers • Direct Renin Inhibitors • Alpha-1 Blockers• Central Alpha2 Agonists• Direct Vasodilators
9
10
9/11/2020
6
Back to our caseBP recheck 144/82ASCVD risk calculator 9.8%Mr Smith has hypertension and should be started on medications • Hydrochlorothiazide 25 mg daily• Lisinopril 5 mg daily • Losartan 25 mg daily• Amlodipine 5 mg daily
• What about his cholesterol
11
12
9/11/2020
7
Statins Block HMG-CoA reductase which inhibits the synthesis of cholesterol in the liver
13
14
9/11/2020
8
Finishing our caseASCVD risk 9.8%“Intermediate Risk”No ASCVD risk enhancers
Mr Smith does not meet criteria for statin therapy. Lipids should be checked again in 6-12 months.
His blood pressure should be monitored in clinic in 1-2 months.
Case 2Mrs Jones is a 72-year-old hispanic female who presents to clinic with complaints of her heart racing and dizziness. She has history of hypertension, hyperlipidemia and coronary artery disease.Vitals
HR – 103BP – 128/72RR – 18O2 – 98%
Meds: • Lisinopril 10 mg daily• Aspirin 81 mg daily• Atorvastatin 80 mg daily• Metoprolol tartrate 50 mg
bidLabs: • NA – 134• BUN – 34• Creatinine – 1.4 • CBC – WNL
15
16
9/11/2020
9
Thoughts
Differential diagnosis • Atrial fibrillation • Atrial flutter• AVNRT • AVRT• Atrial tachycardia• Sinus tachycardia with PACs• Multifocal atrial tachycardia
17
18
9/11/2020
10
Atrial fibrillation • Presence or absence of
clear P waves associated with each QRS
• Regular versus irregular • Normal QRS complex
Atrial fibrillation • Paroxysmal: terminates in <7 days
• Persistent: fails to terminate within 7 days OR intervention necessary to terminate (Ex. DCCV)
• Longstanding persistent: Continue AF duration > 12 months but goal is still rhythm control
• Permanent: Joint decision between patient and clinician not to pursue rhythm control treatment
Most frequent atrial arrhythmia
19
20
9/11/2020
11
Atrial fibrillation management• Resting HR < 80 bpm• 24 hour HR average< 100 bpm• HR < 110 bpm on 6 minute walk• Elevated rates can cause ischemia, hypotension, Type 2 MI, long
term tachycardia can lead to heart failure• Medications
• Beta blockers: oral and IV
• Diltiazem: oral and IV
• Verapamil: oral
• Digoxin: for hypotensive patients
• Amiodarone: rate and rhythm benefit
Rate control
Atrial fibrillation management• Preferred for first diagnosis of afib• Rhytm control options are DCCV, antiarrhythmics, and
ablations• Synchronized DC cardioverstion – emergenices, greater
efficacy than medications• Pharmacoligical cardioversion
• < 7 days atrial fibrillation – dofetilide, sotalol, flecainide, propafenone, amiodarone
• > 7 days atrial fibrillation – dofetilide, sotalol, amiodarone
Rhythm control
21
22
9/11/2020
12
Anticoagulation and DCCV• Atrial fibrillation < 48
hours• No anticoagulation
needed prior to DCCV• Needs oral
anticoagulation for 30 days after DCCV
• Atrial fibrillation > 48 hours
• Needs anticoagulated for 3-4 weeks before DCCV
• If patient is unstable can get TEE prior to DCCV to rule out clot
• Needs oral anticoagulation for 30 days after DCCV
AnticoagulationUse Chads2-vasc to risk stratify patients
0-1 can consider aspirin only versus oral anticoagulation
5-6 should be bridged with heparin/low molecular weight heparin if holding oral anticoagulation
23
24
9/11/2020
13
Oral anticoagulationWarfain – only medication approved for valvular atrial fibrillation, approved for patients with ESRD
Dabigatran (Pradaxa)Rivaroxaban (Xarelto) - approved for patients with ESRDApixiban (Eliquis) - approved for patients with ESRD
DOACs mechanism of action – inhibition of prothorombinasecomplex-bound and clot-associated factor Xa, resulting in a reduction of the thrombin burst during the propgatino phase of the coagulation cascade
My patient can't take anticoagulationWatchman
25
26
9/11/2020
14
Watchman• Self expanding device
that is deployed in the LAA
• FDA approved in March 2015 for patients with nonvalvular atrial fibrillation
• For patients with atrial fibrillation at high risk of stroke
• Patients at high risk of bleeding on oral anticoagulation
• Need to be able to tolerate anticoagulation for 6 weeks currently
Back to our caseMrs Jones has new onset atrial fibrillation and is unsure of when the episode started. She is hemodynamically stable and does not require inpatient admission
Treament of choice – start oral anticoagulation and refer to cardiology for DCCV
Increase metoprolol tartrate to 100 mg bid to assist in rate control
Provide education on emergency signs and symptoms
27
28
9/11/2020
15
Case 3Mr Martin is a 66-year-old African American male being seen for a hospital follow up. He was in the ER with chest pain and shortness of breath on exertion. He was observed overnight, and ACS ruled out. He continues to have SOB with activity and when doing his 1-mile walk gets SOB and pressure halfway through the walk. It resolves when he rests. He has a PMF of hypertension and hyperlipidemia.
Vitals – BP 136/66, HR 74, RR 18, O2 98% on room air
EKG – sinus rhythm, no ST depression
Medications –hydrochlorothiazide 25 mg daily, lisinopril 10 mg daily, atorvastatin 40 mg daily, aspirin 81 mg daily
What would you recommend?
29
30
9/11/2020
16
Cardiac diagnostic toolsEKG – evaluates rate, rhythm, ST elevation, ST depression, Q waves
Laboratory testing – troponin, cbc, cmp, flp
Imaging – echocardiogram, cardiac CT, cardiac MRI, nuclear imaging
To know what test you want, you need to know the results it gives you
EchocardiogramUltrasound technology• Heart size• Heart function• Valve function
• Can be difficult to visualize the RV
31
32
9/11/2020
17
Cardiac CTCT technology• Accurate reconstruction
of the heart and blood vessels
• Can detect calcium build up to detect blockages
• Provides calcium score• Can produce 3D images
Nuclear TestingRadionucleotide testing• MUGA scan• Creates accurate images
of the ventricles to determine function
33
34
9/11/2020
18
Cardiac MRIUse magnetic waves and radiofrequency to create imagesAccurate assessment of• Heart size• Heart function• Myocardium• Inflammation• Scar• Right ventricle
Stress testingTo evaluate for ischemia you need to stress your patient• Exercise versus chemical stress
• Can your patient exercise and provide maximal effort?• HR target is 220-age x 85% for maximal effort
All imaging can also be ordered as a stress test
35
36
9/11/2020
19
Stress tests• Treadmill stress test• Exercise echo• Dobutamine stress echo• Nuclear stress test
•Both exercise and chemical
• CT Angiogram• Adenosine MRI
Pearls• May need to hold beta
blocker prior to test• No caffeine for 24 hours
before nuclear stress test• Cardiac CT requires HR <
65 for more accurate images
• Cardiac MRI requires contrast and is contraindicated in ESRD
Back to our caseMr Martin has DOE which may be an anginal equivalent. He has been ruled out for ACS but should have ischemic evaluation.• Echo or MRI will give cardiac function but no stress• If your patient can exercise order a test that has them
exercising to potentially reproduce symptoms• Exercise echo will provide cardiac function along with
stress images• Can also refer to cardiology for further evaluation
37
38
9/11/2020
20
Case 4Mr Jacobs is a 65-year-old African American male with PMH for severe CAD, s/p CABG in 1994, HTN, HDL, DM-II, and ischemic cardiomyopathy with last ef 15-20%. He comes to clinic for his 6 month follow up. He exhibits NHYA class III symptoms. He denies chest pain, pressure, palpitations, dizziness or lightheadedness. He has trace pedal edema which fluctuates depending on how closely he watches his salt.
Vitals – HR 78, BP – 108/76, RR – 18, BMI – 38Labs – CBC WNL, BUN 42, creatinine 1.4, HgbA1c 8.2Medications – Metoprolol succinate 100 mg daily, Lisinopril 10 mg daily, Furosemide 40 mg daily, Atorvastatin 80 mg daily, Asprin 81 mg daily, Metformin 1000 mg bid
RecommendationsHow is Mr Jacobs doing?
39
40
9/11/2020
21
Heart failure• A syndrome caused by cardiac dysfunction,
generally resulting from myocardial muscle dysfunction or loss and characterized by either LV dilation or hypertrophy or both – HFSA
• The heart is unable to pump sufficiently to need the needs of the body
• Systolic Heart Failure – syndrome characterized by signs and symptoms of HF and reduced LVEF. Commonly associated with LV dilation
• Diastolic Heart Failure or Heart failure with preserved ejection fraction – syndrome characterized by symptoms of HF and preserved LVEF. Commonly associated with nondilated LV
Causes of heart failure• Heart failure with reduced
ejection fraction• Ischemia
• Viruses
• Familial/genetic
• Tachycardia
• Thyroid disease
• Toxins
• Peripartum/postpartum
• Adult congenital heart disease
• Ischemia
• Viruses
• Familial/Genetic
• Heart failure with preserved ejection fraction
• Hypertension• Valvular disease• Constrictive disease• Infiltrative disease
41
42
9/11/2020
22
43
44
9/11/2020
23
Pharmacological treatment• ACE inhibitors/ARBs/ARNI• Beta Blockers• Aldosterone antagonists• Vasodilators• Diuretics• SGLT2 inhibitors –
Approved in 2019/2020
Guideline directed medical therapy (GDMT)
SGLT2 inhibitorsMechanism of action:• Effects on glucose = ↓ reabsorption (kidneys)
• Excreted in urine
• ↓ overall glucose levels
• Excreted in urine
• ↓ overall glucose levels
45
46
9/11/2020
24
Effects of SGLT2 inhibitors
on LV function
SGLT2 inhibitor diuresis effect
47
48
9/11/2020
25
Referral to a heart failure specialistI – IV inotropesN – NYHA IIIB/IV or persistently elevated natriuretic peptidesE – End-organ dysfunction (Cr > 1.8 mg/dL or BUN > 43 mg/dL)E – Ejection fraction < 35%D – Defibrillator shocksH – Hospitalizations > 1E – Edema (or elevated PA pressure) despite escalating diureticsL – Low blood pressure, high heart rateP – Prognostic medication, progressive intolerance or down-titration of guideline directed medical therapy
INEEDHELP
Back to our caseMr Jacobs is stable but continues to exhibit class III symptoms.• Lisinopril should be switched to sacubitril/valsartan with 36
hour wash out period• Metoprolol succinate is not at target dose and can be
titrated up• Diabetes is not under control and SGLT2 inhibitor should
be added• Aldosterone antagonist should be added• Return to clinic in 2 weeks to assess medication tolerance
and fluid retention as diuretic may need adjusted
49
50
9/11/2020
26
Case 5Mrs Alberts is a 55-year-old caucasian female being seen in clinic for worsening SOB and lower extremity edema. She has a PMH of hypertension, hyperlipidemia, HFpEF with echo showing ef of 55-60% with grade III diastolic dysfunction, obesity and OSA. Over the past month she's been more SOB with any activity and has gained 10 pounds. She needs to rest on her walks but does not have PND or orthopnea.
Vitals – HR 88, BP 144/82, RR 20, BMI 42Labs – CBB WNL, BUN 38, creatinine 1.26Medications – Losartan 100 mg daily, amlodipine 5 mg daily, furosemide 80 mg daily, atorvastatin 40 mg daily, levothyroxine 112 mcg daily
Recommendations
51
52
9/11/2020
27
HFpEF
HFpEF guidelines• Treat underlying medical conditions
• Management of hypertension• Management of OSA
• Use of aldosterone antagonists• Use of ARBs
53
54
9/11/2020
28
CardioMEMSCardioMEMS remotely monitors changes in pulmonary artery (PA) pressures• Sensor is implants in the distal pulmonary artery via a right
heart catherization• Sensor daily measures pressures in the PA• Pressures are downloaded and sent remotely by patient
• Reduces heart failure hospitalizations• Lowers mortality• Improves quality of life and functional capacity
CardioMEMS
55
56
9/11/2020
29
Back to our caseMrs Alberts has signs of fluid overload related to her HFpEF• Her OSA is treated with CPAP• Blood pressures are slightly elevated• Aldosterone antagonist recommended – spironolactone 25
mg daily• Potential diuretic resistance and can be switched to
torsemide 80 mg daily• Refer to cardiology for CardioMEMS implant
57
58
9/11/2020
30
59
top related